Potential of cannabinoids as treatments for autism spectrum disorders.
Autism spectrum disorders
Cannabinoids
Journal
Journal of psychiatric research
ISSN: 1879-1379
Titre abrégé: J Psychiatr Res
Pays: England
ID NLM: 0376331
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
27
01
2021
accepted:
22
02
2021
pubmed:
11
3
2021
medline:
21
5
2021
entrez:
10
3
2021
Statut:
ppublish
Résumé
Current treatments for autism spectrum disorders (ASD) are limited in efficacy and are often associated with substantial side effects. These medications typically ameliorate problem behaviors associated with ASD, but do not target core symptom domains. As a result, there is a significant amount of research underway for development of novel experimental therapeutics. Endocannabinoids are arachidonic acid-derived lipid neuromodulators, which, in combination with their receptors and associated metabolic enzymes, constitute the endocannabinoid (EC) system. Cannabinoid signaling may be involved in the social impairment and repetitive behaviors observed in those with ASD. In this review, we discuss a possible role of the EC system in excitatory-inhibitory (E-I) imbalance and immune dysregulation in ASD. Novel treatments for the core symptom domains of ASD are needed and phytocannabinoids could be useful experimental therapeutics for core symptoms and associated domains.
Identifiants
pubmed: 33689997
pii: S0022-3956(21)00126-6
doi: 10.1016/j.jpsychires.2021.02.048
pii:
doi:
Substances chimiques
Cannabinoids
0
Endocannabinoids
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
194-201Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.